Related Experiment Videos
Papillomaviruses as targets for cancer gene therapy
E J Shillitoe1, P Kamath, Z Chen
1Department of Microbiology and Immunology, SUNY College of Medicine, Syracuse 13210, USA.
Abstract:
Gene therapy of human cancer is likely to be most effective when it is directed at targets that are expressed in cancer cells but are lacking from other cells. Human papillomaviruses can provide such targets, since these viruses are present in many cervical and oral cancers, and are likely to be etiological agents of the tumor. Continued expression of human papillomavirus genes is probably necessary for the growth of these cancers, and effective gene therapy could consist of antisense or ribozyme molecules directed against these genes. Some human papillomavirus gene products are antigenic, and immunotherapy based upon these antigens might prove clinically beneficial. Human papillomaviruses have specific promoters, are linked to toxin genes, the toxin may be selectively expressed by tumor cells where the virus genes are active. Thus, there are several approaches for the development of specific gene therapy for human cancers that contain human papillomaviruses.
Insights
Human papillomaviruses (HPVs) offer specific targets for gene therapy in cervical and oral cancers. Strategies include using antisense or ribozyme molecules against HPV genes for effective cancer treatment.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Human papillomaviruses (HPVs) are implicated in the etiology of cervical and oral cancers.
- Tumor growth often depends on the continued expression of specific HPV genes.
Purpose of the Study:
- To explore gene therapy strategies targeting HPV in cancer.
- To identify specific molecular targets within HPV for therapeutic intervention.
Main Methods:
- Development of antisense or ribozyme molecules targeting essential HPV genes.
- Investigating immunotherapy approaches utilizing HPV-encoded antigens.
- Engineering toxin genes under the control of HPV-specific promoters for selective tumor cell killing.
Main Results:
- HPV provides tumor-specific targets, enhancing gene therapy efficacy.
- Antisense/ribozyme strategies can inhibit HPV gene expression.
- Immunotherapy against HPV antigens shows potential clinical benefit.
- Targeted toxin delivery via HPV promoters offers selective cancer cell destruction.
Conclusions:
- Gene therapy approaches targeting human papillomaviruses present a promising strategy for treating HPV-associated cancers.
- The specificity of HPV in cancer cells allows for targeted therapeutic interventions, minimizing off-target effects.